pnb-0408 dihexa clinical trial 30 Tablets 8mg Dihexa Capsules | Research Use

[DOI] [PubMed] [Google Scholar] 188.Butterworth J.F., IV

Keith Lafferty MD, Fort Myers on June 29, 2025

Disclosure of interest: Name of author: nothing to disclose Poster session I - DIAGNOSIS / ETIOLOGY 04.00 - DIAGNOSIS / ETIOLOGY - 04.10 - ESUS/CRYPTOGENIC STROKE P330 - ESOC25-180 LEFT VENTRICULAR DISEASE AS A RISK FACTOR FOR ADVERSE OUTCOMES AND STROKE RECURRENCE IN PATIENTS WITH EMBOLIC STROKE OF UNDETERMINED SOURCE Angelo Cascio Rizzo 1 , Ghil Schwarz, Andrea Bonelli 1 , Andrea Magi 2 , Elio Agostoni 1 , Antonella Moreo 1 , Maria Sessa 1 ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy, 2 University of Milano-Bicocca, Milan, Italy Background and Aims: LV disease (LVD), such as mild-to-moderate LV dysfunction and LV wall-motion-abnormalities (LVWMA), are considered potential minor cardiac sources in ESUS, but their role is underexplored

For others, it takes a day or two

However, M1/M2 high tumors enriched gene sets related to cell proliferation and cell cycles with GSEA in METABRIC cohort only

Injection Site Rotation Rotate injection sites to prevent lipodystrophy (fat tissue changes at the injection site)